Trial Profile
A Single-Center, Retrospective, Observational Study Investigating Nivolumab Therapy in Patients with Recurrent/Advanced Squamous Cell Head and Neck Carcinoma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 27 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.